A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders
- PMID: 35236262
- PMCID: PMC9886837
- DOI: 10.2174/1570159X20666220302152400
A Possible Causal Involvement of Neuroinflammatory, Purinergic P2X7 Receptors in Psychiatric Disorders
Abstract
P2X7 receptors (Rs) are prominent members of the P2XR family, which after binding ATP, open non-selective cationic channels, thereby allowing the transmembrane passage of Na+, Ca2+, and K+. Long-lasting and repetitive stimulation of the receptor by its agonist leads to the formation of large membrane pores permeable for organic cations of up to 900 Da molecular size. These pores are believed to play a role in apoptosis and inflammation. P2X7Rs are located primarily at peripheral macrophages and microglial cells, the resident macrophages of the CNS. The coactivation of toll-like receptors 4 (TLR4) by lipopolysaccharide, a constituent of the cell membrane of gram-negative bacteria, and the P2X7R by ATP leads to the generation and release of the proinflammatory cytokines interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α. Together with the microglial release of chemokines, reactive oxygen and nitrogen species, proteases, and excitotoxic glutamate, these cytokines result in neurodegeneration. P2X7Rs were found not only to amplify various neurodegenerative illnesses, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, but also to participate in a range of psychiatric diseases, such as major depression, bipolar disorder, schizophrenia, and autism spectrum disorder. Based on the prevention/reversal of neuroinflammation, pharmacological antagonists of P2X7Rs and their genetic deletion in animal experiments counteract these deleterious psychiatric conditions. Hence, brain penetrant P2X7R antagonists are potential therapeutics for psychiatric diseases, although the available evidence still needs to be extended and validated by further clinical data.
Keywords: P2X7 receptor; clinical data; interleukin-1β; neurodegeneration; neuroinflammation; psychiatric disorders.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Figures
Similar articles
-
P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.Int J Mol Sci. 2020 Aug 20;21(17):5996. doi: 10.3390/ijms21175996. Int J Mol Sci. 2020. PMID: 32825423 Free PMC article. Review.
-
Ethanol differentially modulates P2X4 and P2X7 receptor activity and function in BV2 microglial cells.Neuropharmacology. 2018 Jan;128:11-21. doi: 10.1016/j.neuropharm.2017.09.030. Epub 2017 Sep 22. Neuropharmacology. 2018. PMID: 28943285 Free PMC article.
-
Inherent P2X7 Receptors Regulate Macrophage Functions during Inflammatory Diseases.Int J Mol Sci. 2021 Dec 26;23(1):232. doi: 10.3390/ijms23010232. Int J Mol Sci. 2021. PMID: 35008658 Free PMC article. Review.
-
The neuroinflammatory astrocytic P2X7 receptor: Alzheimer's disease, ischemic brain injury, and epileptic state.Expert Opin Ther Targets. 2023 Jul-Dec;27(9):763-778. doi: 10.1080/14728222.2023.2258281. Epub 2023 Sep 15. Expert Opin Ther Targets. 2023. PMID: 37712394 Review.
-
Involvement of P2X7 receptors in chronic pain disorders.Purinergic Signal. 2022 Mar;18(1):83-92. doi: 10.1007/s11302-021-09796-5. Epub 2021 Nov 20. Purinergic Signal. 2022. PMID: 34799827 Free PMC article. Review.
Cited by
-
Commentary: P2X7 receptor modulation is a viable therapeutic target for neurogenic pain with concurrent sleep disorders.Front Neurosci. 2023 Nov 30;17:1293174. doi: 10.3389/fnins.2023.1293174. eCollection 2023. Front Neurosci. 2023. PMID: 38099200 Free PMC article. No abstract available.
-
P2X7 receptor-activated microglia in cortex is critical for sleep disorder under neuropathic pain.Front Neurosci. 2023 Feb 3;17:1095718. doi: 10.3389/fnins.2023.1095718. eCollection 2023. Front Neurosci. 2023. PMID: 36816134 Free PMC article.
-
Short-chain fatty acids in patients with schizophrenia and ultra-high risk population.Front Psychiatry. 2022 Dec 12;13:977538. doi: 10.3389/fpsyt.2022.977538. eCollection 2022. Front Psychiatry. 2022. PMID: 36578297 Free PMC article.
References
MeSH terms
Substances
Grants and funding
- CZYHW1901/Chengdu University of Traditional Chinese Medicine
- G20190236012/State Administration of Foreign Affairs
- ZYYCXTD-D-202003/Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine
- 2019YFH0108, 2022YFH0006/Sichuan Science and Technology Program
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
